In summary, this population-based study demonstrated an improvement in real-world overall survival during the COVID-19 pandemic among a specific group of lung cancer patients undergoing pembrolizumab-based treatment: those with PD-L1 expression level < 50% treated with pembrolizumab monotherapy. This evidence concerns the gene CD274 and lung carcinoma.